Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus
Authors
Keywords
-
Journal
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
Volume 42, Issue 2, Pages 125-138
Publisher
Wiley
Online
2014-10-31
DOI
10.1111/1440-1681.12332
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SGLT-2 inhibitors as second-line therapy in type 2 diabetes
- (2014) Abd A Tahrani Lancet Diabetes & Endocrinology
- Rivoglitazone: A New Thiazolidinedione for the Treatment of Type 2 Diabetes Mellitus
- (2013) Robin L Koffarnus et al. ANNALS OF PHARMACOTHERAPY
- Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus
- (2013) Christian Friedrich et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Metformin Retards Aging in C. elegans by Altering Microbial Folate and Methionine Metabolism
- (2013) Filipe Cabreiro et al. CELL
- Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects
- (2013) Stephan A. Veltkamp et al. CLINICAL DRUG INVESTIGATION
- Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
- (2013) Rajendra H. Jani et al. CLINICAL DRUG INVESTIGATION
- Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment
- (2013) S. Macha et al. DIABETES OBESITY & METABOLISM
- Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
- (2013) T. Heise et al. DIABETES OBESITY & METABOLISM
- Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
- (2013) C. S. Kovacs et al. DIABETES OBESITY & METABOLISM
- A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
- (2013) E. Ferrannini et al. DIABETES OBESITY & METABOLISM
- Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis
- (2013) J. A. Hirst et al. DIABETOLOGIA
- Canagliflozin: First Global Approval
- (2013) Shelley Elkinson et al. DRUGS
- Synthesis of novel triterpene and N-allylated/N-alkylated niacin hybrids as α-glucosidase inhibitors
- (2013) Tadigoppula Narender et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Mitiglinide for type 2 diabetes treatment
- (2013) Haley M Phillippe et al. EXPERT OPINION ON PHARMACOTHERAPY
- Antidiabetic agents: past, present and future
- (2013) Ahmed Mehanna Future Medicinal Chemistry
- Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus
- (2013) Damayanthi Devineni et al. JOURNAL OF CLINICAL PHARMACOLOGY
- SGLT2 inhibitors for diabetes: turning symptoms into therapy
- (2013) Michaela Diamant et al. LANCET
- Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP
- (2013) Russell A. Miller et al. NATURE
- PPARγ signaling and metabolism: the good, the bad and the future
- (2013) Maryam Ahmadian et al. NATURE MEDICINE
- Optimal management of T2DM remains elusive
- (2013) Rury R. Holman Nature Reviews Endocrinology
- Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data
- (2013) Eiji Kurosaki et al. PHARMACOLOGY & THERAPEUTICS
- Glucagon-like peptide 1 and appetite
- (2013) Megan J. Dailey et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Amylin Uncovered: A Review on the Polypeptide Responsible for Type II Diabetes
- (2013) Karen Pillay et al. Biomed Research International
- Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus
- (2013) Elizabeth K Hussey et al. BMC Pharmacology & Toxicology
- Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, Coadministered with Sitagliptin in Healthy Volunteers
- (2012) Tobias Brand et al. ADVANCES IN THERAPY
- Mini-Special Issue paper Management of diabetic patients with hypoglycemic agents α-Glucosidase inhibitors and their use in clinical practice
- (2012) Giuseppe Derosa et al. Archives of Medical Science
- Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus
- (2012) Masakazu Imamura et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin
- (2012) Ulrike Graefe-Mody et al. CLINICAL PHARMACOKINETICS
- Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin
- (2012) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
- Liraglutide: from clinical trials to clinical practice
- (2012) S. C. L. Gough DIABETES OBESITY & METABOLISM
- An Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists
- (2012) Krystal L. Edwards et al. Diabetes Technology & Therapeutics
- Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial
- (2012) M. Nauck et al. DIABETIC MEDICINE
- Dapagliflozin
- (2012) Greg L. Plosker DRUGS
- Linagliptin
- (2012) Emma D. Deeks DRUGS
- Repaglinide
- (2012) Lesley J. Scott DRUGS
- Drug-induced hypoglycaemia in type 2 diabetes
- (2012) Berit Inkster et al. Expert Opinion On Drug Safety
- Thiazolidinedione safety
- (2012) Jacqueline Kung et al. Expert Opinion On Drug Safety
- A review of the efficacy and safety of oral antidiabetic drugs
- (2012) Stephanie Aleskow Stein et al. Expert Opinion On Drug Safety
- Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus
- (2012) Vivian A. Fonseca et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Metformin pathways
- (2012) Li Gong et al. Pharmacogenetics and Genomics
- Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects
- (2012) Arian Emami Riedmaier et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction
- (2012) Sheldon Russell International Journal of Clinical Pharmacy
- Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses
- (2012) B. Hemmingsen et al. BMJ-British Medical Journal
- Cardiovascular Effects of Anti-Diabetic Medications in Type 2 Diabetes Mellitus
- (2012) Samar Singh et al. Current Cardiology Reports
- Cellular and molecular mechanisms of metformin: an overview
- (2011) Benoit Viollet et al. CLINICAL SCIENCE
- Bile acid sequestrants
- (2011) Carolien Out et al. CURRENT OPINION IN LIPIDOLOGY
- DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
- (2011) A.J. Scheen DIABETES & METABOLISM
- Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus
- (2011) Sherwyn L. Schwartz et al. Diabetes Technology & Therapeutics
- Pramlintide and the treatment of diabetes: a review of the data since its introduction
- (2011) Lisa M Younk et al. EXPERT OPINION ON PHARMACOTHERAPY
- Sitagliptin: a review
- (2011) Sreevidya Subbarayan et al. EXPERT OPINION ON PHARMACOTHERAPY
- The effects of food on the pharmacokinetics of mitiglinide tablets in healthy volunteers and a novel mass-spectrometric (UPLC-MS/MS) method for such studies
- (2011) J. Zhang et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Incretin-based therapies
- (2011) Anthony H. STONEHOUSE et al. Journal of Diabetes
- The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the α2-adrenergic receptors in beta cells
- (2010) J.E. de Leeuw van Weenen et al. BIOCHEMICAL PHARMACOLOGY
- Bromocriptine: old drug, new formulation and new indication
- (2010) R. I. G. Holt et al. DIABETES OBESITY & METABOLISM
- Multiple-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double-Blind Study
- (2010) Elizabeth K. Hussey et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Single-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus
- (2010) Elizabeth K. Hussey et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Discovery of Canagliflozin, a NovelC-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus(1)
- (2010) Sumihiro Nomura et al. JOURNAL OF MEDICINAL CHEMISTRY
- Adjunct therapy for type 1 diabetes mellitus
- (2010) Harold E. Lebovitz Nature Reviews Endocrinology
- Ranirestat for the Management of Diabetic Sensorimotor Polyneuropathy
- (2009) V. Bril et al. DIABETES CARE
- Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
- (2008) P COVINGTON et al. CLINICAL THERAPEUTICS
- Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
- (2008) D. M. Nathan et al. DIABETOLOGIA
- Bezafibrate, a Peroxisome Proliferator-Activated Receptors Agonist, Decreases Body Temperature and Enhances Electroencephalogram Delta-Oscillation during Sleep in Mice
- (2008) Sachiko Chikahisa et al. ENDOCRINOLOGY
- Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy
- (2008) Mary Ann Ramirez et al. PHARMACOTHERAPY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started